MedTrace Logo

The Use of Finasteride to Reduce Hematuria and Hematospermia Following TRUS Prostate Biopsy

NCT00600691 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2014-01-31

No results posted yet for this study

Summary

The purpose of our study is primarily to evaluate the effects of 5mg finasteride on hematuria and hematospermia commonly associated with prostate biopsies. We hypothesize that 5mg of finasteride daily for two weeks preceding TRUS prostate biopsy and one week following will reduce hematuria and hematospermia commonly seen as complications following prostate biopsy. We also hypothesize that reducing complications will decrease concern among subjects and make for a more tolerable overall procedure than compared with subjects treated with placebo.

Conditions

  • Hematuria
  • Hematospermia

Interventions

DRUG

Finasteride

one tablet (5mg) of finasteride

Sponsors & Collaborators

  • Health Canada

    collaborator OTHER_GOV

  • Merck Frosst Canada Ltd.

    collaborator INDUSTRY

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Peter Pommerville, MD · University of British Columbia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00600691 on ClinicalTrials.gov